Clinical Trial Detail

NCT ID NCT02889861
Title IMCgp100-401 Rollover Study
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Immunocore Ltd
Indications

melanoma

Therapies

Tebentafusp

Age Groups: adult senior

No variant requirements are available.